Janssen will use DCOne technology from DCPrime for dendritic cell-based cancer vaccine
Dutch cancer vaccine company DCPrime, based in Leiden, has entered into a research and optional licensing agreement with Janssen Pharmaceuticals. The collaboration has been facilitated in conjunction with the Johnson & Johnson London Innovation Centre, where a team of business, science and transaction experts are identifying and building novel early-stage collaborations with emerging companies.
Under the agreement, Janssen will use DCPrime’s DCOne technology in feasibility studies for the development of a dendritic cell-based vaccine. Additionally, Janssen will have the option to further develop a drug candidate towards regulatory approval.
'DCPrime is always looking for new opportunities for our DCOne technology,' said Marcel Zwaal, CEO of DCPrime. 'We are very excited to be able to work with Janssen and it will enable us to further extend the use our vaccine products.'